



an Open Access Journal by MDPI

# Harmful Marine Phytoplankton

Guest Editors:

#### Dr. Wenche Eikrem

 Marin Biogeochemistry and Oceanography, Norwegian Institute for Water Research, Gaustadalléen 21, 0349 Oslo, Norway
Department of Biosciences, University of Oslo, Oslo, Norway

#### Dr. Anette Engesmo

Marin Biogeochemistry and Oceanography, Norwegian Institute for Water Research. Gaustadalléen 21, 0349 Oslo, Norway

Deadline for manuscript submissions: closed (30 September 2017)

### Message from the Guest Editors

Dear Colleagues,

During the last few decades. harmful marine phytoplankton has received significant attention from the scientific community. The consensus is that bloom events are increasing in frequency and practically every coastal region in the world is affected. Increasing our knowledge about the causative species, the toxins they produce and the impact they have on the marine environment is a huge task and in this Special Issue we will publish high quality papers regarding all aspects of harmful marine microalgae, also including toxin producing cyanobacteria.

We cordially invite you to submit your research to this Special Issue of *Marine Drugs*, and we look very much forward to your input.

Dr. Wenche Eikrem Dr. Anette Engesmo *Guest Editors* 









an Open Access Journal by MDPI

# **Editor-in-Chief**

#### Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

### Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

# **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

## **Contact Us**

Marine Drugs Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/marinedrugs marinedrugs@mdpi.com X@Marine\_Drugs